Abstract

OSORIO, José Henry. METABOLIC AND CLINICAL IMPLICATIONS OF SOME DESIGNED DRUGS. Biosalud [online]. 2013, vol.12, n.2, pp.110-117. ISSN 1657-9550.

Background: Designer drugs of the amphetamine, benzyl, phenyl piperazine, or pyrrolidinophenone type produce feelings of euphoria and energy and a desire to socialize, reason why they are known as "rave drugs" or "club drugs". Although consumers adduce that these are safe drugs, experimental studies using bio models and epidemiological studies in humans, indicate potential risks for users. Materials and Methods: The review article analyses quantitatively scientific literature from Science Direct and PUBMED data bases related to metabolism of these drugs and their implications in health. Results: Relevant information related to the objectives proposed in the present review was found and it can be classified in 2 sections as follows: metabolism of designer drugs and clinical implications of consumption of designer drugs. Conclusion: The metabolic pathways which involve P450 isoenzymes are responsible for hepatic degradation of designer drugs. There are potential risks for consumers such as serotonin syndrome, hepatotoxicity, neurotoxicity, and psychopathology.

Keywords : abuse drugs; designer drugs; ecstasy; piperazine; pyrrolidinophenone; metabolism.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )